Boston Scientific Corporation
BSX
$101.08
$2.162.18%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 22.44% | 19.34% | 14.48% | 13.78% | 14.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.44% | 19.34% | 14.48% | 13.78% | 14.90% |
| Cost of Revenue | 27.37% | 18.44% | 19.53% | 15.98% | 13.09% |
| Gross Profit | 20.22% | 19.75% | 12.34% | 12.79% | 15.73% |
| SG&A Expenses | 16.90% | 25.76% | 6.79% | 12.26% | 18.57% |
| Depreciation & Amortization | 8.17% | -1.44% | 1.43% | 5.42% | 4.52% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.33% | 19.64% | 10.96% | 12.72% | 14.43% |
| Operating Income | 28.04% | 17.90% | 31.85% | 18.87% | 17.30% |
| Income Before Tax | 15.84% | 9.67% | -1.41% | 36.63% | 27.85% |
| Income Tax Expenses | 2,200.00% | 90.48% | -37.18% | -12.21% | -99.61% |
| Earnings from Continuing Operations | 11.51% | -7.13% | 19.26% | 57.01% | 260.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 300.00% | -- | -- | -- | -- |
| Net Income | 12.08% | -7.13% | 20.00% | 57.32% | 260.71% |
| EBIT | 28.04% | 17.90% | 31.85% | 18.87% | 17.30% |
| EBITDA | 22.37% | 12.65% | 22.79% | 14.86% | 13.41% |
| EPS Basic | 11.23% | -7.63% | 22.05% | 61.37% | 292.04% |
| Normalized Basic EPS | 31.86% | 22.72% | 39.73% | 20.85% | 9.90% |
| EPS Diluted | 11.97% | -6.32% | 22.22% | 57.97% | 285.78% |
| Normalized Diluted EPS | 31.51% | 22.39% | 39.41% | 20.68% | 9.74% |
| Average Basic Shares Outstanding | 0.61% | 0.56% | 1.69% | 2.27% | 2.28% |
| Average Diluted Shares Outstanding | 0.90% | 0.84% | 1.92% | 2.47% | 2.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -1.00% |